Cargando…
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
Background: Aromatase inhibitors (AIs) are associated with musculoskeletal pain in one third (20–47%) of breast cancer patients. Recently, CDK4/6 inhibitors have emerged as a new therapeutic approach in hormone receptor (HR)-positive breast cancer. While hematological and gastrointestinal toxicities...
Autores principales: | Andrikopoulou, Angeliki, Fiste, Oraianthi, Apostolidou, Kleoniki, Skafida, Efthymia, Markellos, Christos, Liontos, Michalis, Kyriazoglou, Anastasios, Dimopoulos, Meletios-Athanasios, Zagouri, Flora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293403/ https://www.ncbi.nlm.nih.gov/pubmed/34198899 http://dx.doi.org/10.3390/medsci9020042 |
Ejemplares similares
-
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021) -
Subarachnoid hemorrhage in a postpartum mother: A rare manifestation of an uncommon disease
por: Fiste, Oraianthi, et al.
Publicado: (2022) -
Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022) -
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021) -
Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)